| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 424492000 | Gelatin | 44 |
| 20080260843 | TRANSPULMONARY COMPOSITION - It is an object of the present invention to provide a transpulmonary preparation wherein physiologically active ingredient can be stably retained and which has high absorption efficacy and gives low damage to tissue. The present invention provides a transpulmonary preparation which comprises protein nanoparticles containing an active ingredient and having an average particle size of 200 nm to 500 nm. | 10-23-2008 |
| 20090238887 | Highly Impact-Resistant Granules - The present invention provides highly impact-resistant, water-soluble or water dispersible, low-dust granules comprising an active ingredient and methods for obtaining the same. | 09-24-2009 |
| 20100021549 | Microparticle oral form useful for the modified release of nanoparticles - The present invention aims to propose novel microparticle oral forms for the modified release of active ingredient(s), in particular protein or peptide in nature. It also relates to the uses, in particular therapeutic or cosmetic, of these microparticle oral forms. | 01-28-2010 |
| 20100166871 | VERMIN POISON - Use of an orally or nasally available formulation of Tretazicar for poisoning vermin. An orally available or nasally available formulation of Tretazicar, wherein in the orally available formulation the Tretazicar is protected from acid hydrolysis, and provided that the formulation is not solid Tretazicar in a gelatin capsule. A formulation of Tretazicar in which the Tretazicar is protected from acid hydrolysis, wherein the formulation is present in a liquid form. A combination of Tretazicar and bait. A method of poisoning vermin comprising making available to the vermin an orally or nasally available formulation of Tretazicar and allowing the vermin to ingest or inhale the formulation of Tretazicar. | 07-01-2010 |
| 20100173002 | Microcapsules with improved shells - Disclosed are microcapsules and methods for preparing and using them, as well as methods for improving various properties of microcapsules like impermeability. | 07-08-2010 |
| 20100209519 | PHARMACEUTICAL COMPOSITION FOR INHALATION DELIVERY AND FABRICATION METHOD THEREOF - A pharmaceutical composition for inhalation delivery is provided, including drugs and a gelatin nanoparticle encapsulating the drugs to form a drug-gelatin nanocomplex, wherein the surface of the gelatin nanoparticle is modified with cell-targeting molecules. A method for fabricating the pharmaceutical composition for inhalation delivery is also provided. | 08-19-2010 |
| 20100260858 | DRUG DELIVERY COMPOSITION - A composition for delivery of a drug is disclosed. The composition has a semipermeable coating, particles of a medicament having an effective average particle size of less than or about 2 μm and at least one surface stabilizer adsorbed on the surface of the medicament particles, and a solubilizing agent. | 10-14-2010 |
| 20100266705 | NANOPARTICULATE MEGESTROL FORMULATIONS - The present invention is directed to nanoparticulate compositions comprising megestrol. The megestrol particles of the composition have an effective average particle size of less than about 2000 nm. | 10-21-2010 |
| 20110165256 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPLASIA - In accordance with the present invention, there are provided methods for treating hyperplasia in a subject in need thereof. In another aspect of the invention, there are provided methods for reducing neointimal hyperplasia associated with vascular interventional procedures. Formulations contemplated for use herein comprise proteins and at least one pharmaceutically active agent. | 07-07-2011 |
| 20110206771 | Encapsulated functional fine particle composition capable of spraying and preparation method thereof - Provided is an encapsulated functional fine particle composition capable of spraying that is useful for hemostasis and wound protection and allows a patient to treat the wound by oneself. Additionally, the composition can be rapidly applied on a large wound during an operation using an air gun in case of in-vivo application and shows prompt hemostasis. | 08-25-2011 |
| 20110236494 | CIPROFLOXACIN ORAL SUSPENSION - The present invention relates to oral taste masked pharmaceutical composition comprising ciprofloxacin or salts or esters thereof. It further relates to processes of preparing it. | 09-29-2011 |
| 20110256229 | RAPID-ACTING PHARMACEUTICAL COMPOSITION - A pharmaceutical composition for the treatment of acute disorders is described. The composition comprises an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carrier particles which are substantially larger than the particles of the active agent or agents, and are essentially insoluble or sparingly soluble in water, in combination with a bioadhesion and/or mucoadhesion promoting agent adhered to the surfaces of said carrier particles. The composition is primarily intended for sublingual or intranasal administration. The invention also relates to a method for preparing the composition and to the use of the composition for the treatment of acute disorders. | 10-20-2011 |
| 20120015038 | ENTERICALLY COATED CYSTEAMINE, CYSTAMINE AND DERIVATIVES THEREOF - The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects. | 01-19-2012 |
| 20120021058 | PROCESS FOR MAKING DRY AND STABLE HEMOSTATIC COMPOSITIONS - Described is a process for making a dry and stable hemostatic composition, said process comprising
| 01-26-2012 |
| 20120040008 | PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE 5 RECEPTOR (MGLU5) ANTAGONISTS - Pharmaceutical compositions of metabotropic glutamate 5 receptor (mGlu5) antagonists or a pharmacologically acceptable salt thereof are disclosed. The compositions contain the therapeutic active compound with non-ionic polymer and ionic polymer, binder and fillers in either matrix pellet, matrix tablet or coated pellets. The compositions provide a pH-independent in vitro release profile with NMT 70% in one hour, NMT 85% in 4 hour, and NLT 80% in 8 hours. The compositions are useful for the treatment of CNS disorders, such as Treatment-Resistant Depression (TRD) and Fragile X Syndrome. | 02-16-2012 |
| 20120076863 | NANOPARTICULATE STABILIZED ANTI-HYPERTENSIVE COMPOSITIONS - The present invention is directed to anti-hypertensive compositions comprising a nanoparticulate temocapril, or a salt or derivative thereof, having improved bioavailability. The nanoparticulate temocapril particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the treatment of hypertension and related diseases. | 03-29-2012 |
| 20120076864 | Microcapsules Containing Microorganisms - Microcapsules for delivery of a liquid onto a surface such as a hard surface or a textile, such as mattress ticking, are disclosed. The microcapsules have a shell with an outer face and an inner face, the inner face encapsulating the liquid, and the liquid contains a microorganism such as a beneficial microorganism in a dormant state. The outer face of the microcapsules may comprise reactive functional groups whereby the outer face is chemically bondable, for instance covalently bondable to said surface. | 03-29-2012 |
| 20120128780 | NANOPARTICULATE BISPHOSPHONATE COMPOSITIONS - Nanoparticulate bisphosphonate compositions, having an effective average particle size of less than 2000 nm, are described. The compositions are useful in treating bone resorption in a mammal. | 05-24-2012 |
| 20120315336 | INJECTABLE NANOPARTICULATE OLANZAPINE FORMULATIONS - Described are injectable formulations of particulate olanzapine that produce a prolonged duration of action upon administration, and methods of making and using such formulations. The injectable formulations comprise particulate olanzapine. | 12-13-2012 |
| 20130039990 | INJECTABLE, LOAD-BEARING CELL/MICROBEAD/CALCIUM PHOSPHATE BONE PASTE FOR BONE TISSUE ENGINEERING - The invention provides injectable, stem cell-containing calcium phosphate bone pastes for bone tissue engineering and methods of making and using the same. | 02-14-2013 |
| 20130084340 | Compositions and Methods of Making Sustained Release Liquid Formulations - The present invention includes compositions and methods for the controlled release of active agents in a shelf-stable liquid formulation by blending one or more controlled release microbeads comprising one or more active agents, preparing a dense, thixotropic solution having a density that is at, or about, the density of the one or more microbeads comprising a thixotropic agent, water and one or more preservatives under conditions that reduce bubble formation and mixing the microbeads and the thixotropic solutions in a mixer that lacks scraping paddles. | 04-04-2013 |
| 20130101673 | COMPOSITIONS AND THEIR USE IN BONE HEALING - The present invention is directed to implantable compositions comprising substantially spherical bioactive glass particles. | 04-25-2013 |
| 20130189366 | DRUG DELIVERY SYSTEMS AND METHODS OF USE - Disclosed herein are systems for delivery of one or more molecules (such as a drug, for example, a small molecule, polypeptide, and/or nucleic acid) to a subject, for example to a targeted location in the subject. In some embodiments, the delivery system includes an encapsulated inducing agent or repressing agent and a plurality of cells. In some examples, the inducing agent or repressing agent and the cells are each separately encapsulated. In other examples, the encapsulated inducing agent or repressing agent and the cells are co-encapsulated. The cells include one or more genes which are operably linked to an inducible promoter or a repressible promoter which is inducible or repressible by the encapsulated inducing agent or repressing agent, respectively. Methods of use of the delivery systems, for example to treat or inhibit a disease or disorder in a subject, are also disclosed. | 07-25-2013 |
| 20130309313 | Compositions and Methods for Increasing the Stability of Food Product Additives - Disclosed are compositions including powdered green tea extract and a powdered preparation comprising polyunsaturated fatty acids. Also disclosed are methods of preparing the compositions and using the compositions in food products, as well as food products containing or that are prepared from the compositions. | 11-21-2013 |
| 20130330411 | PHARMACEUTICAL CYCLOSPORIN COMPOSITIONS - An oral cyclosporin composition comprises minicapsules having a core containing a cyclosporin, especially cyclosporin A in a solubilised liquid form. The minicapsules have a release profile to release the pre-solubilised cyclosporin, at least in the colon. The composition may be used for treating a range of intestinal diseases [FIG. | 12-12-2013 |
| 20140017324 | MULTIPARTICULATE L-MENTHOL FORMULATIONS AND RELATED METHODS - An L-menthol-containing multiparticulate formulation includes a plurality of individual enteric coated cores containing L-menthol from an at least 80% pure L-menthol source. The enteric coated cores are effective to release at least about 35% of the L-menthol within about two hours, and at least about 80% of the L-menthol within about eight hours after being placed in an environment having a pH of 5 to 8. The L-menthol multiparticulate formulation can be used to treat gastrointestinal disorders. | 01-16-2014 |
| 20140017325 | ENTERIC COATED MULTIPARTICULATE CONTROLLED RELEASE PEPPERMINT OIL COMPOSITION AND RELATED METHODS - A multiparticulate composition is formed from a plurality of individual cores including a hydrophobic phase containing peppermint oil dispersed in a microcrystalline cellulose-based gel and a hydrophilic phase containing a hydrogel. An enteric coating is over the individual cores. The multiparticulate composition can be used to treat gastrointestinal disorders. | 01-16-2014 |
| 20140030348 | DOSAGE FORMS FOR ORAL ADMINISTRATION AND METHODS OF TREATMENT USING THE SAME - The invention relates to dosage forms that provide prolonged therapy. In particular, the invention relates to dosage forms including various pluralities of drug-containing resin particles. The invention also relates to methods of making these dosage forms and methods of treating using these dosage forms. | 01-30-2014 |
| 20140044793 | MICROENCAPSULATION PROCESS AND PRODUCT - A composition comprising a core material, having a taste value and a polymeric coating. The polymeric coating substantially surrounds the core material and comprises a cationic polymer and optionally an anionic polymer. The polymeric coating has a uniform thickness ranging from 2 μm to 20 μm. The composition provides release of a portion of the core material which is taste masked over a time period ranging from 0.5 minute to 2 minutes in the oral cavity and provides a modified-release of the remaining core material in a gastrointestinal tract. | 02-13-2014 |
| 20140093576 | Pharmaceutical Dosage Form with Multiple Coatings for Reduced Impact of Coating Fractures - The present invention relates to a pharmaceutical composition in a solid unit dosage form for oral administration in a human or lower animal comprising: a. a safe and effective amount of a therapeutically active agent; b. an inner coating layer selected from the group consisting of poly(methacrylic acid, methyl methacrylate) 1:2, poly(methacrylic acid, methyl methacrylate) 1:1, and mixtures thereof; and c. an outer coating layer comprising an enteric polymer or film coating material; wherein the inner coating layer is not the same as the outer coating layer; wherein if the inner coating layer is poly(methacrylic acid, methyl methacrylate) 1:1 then the outer coating layer is not poly(methacrylic acid, methyl methacrylate) 1:2 or is not a mixture of poly(methacrylic acid, methyl methacrylate) 1:1 and poly(methacrylic acid, methyl methacrylate) 1:2; and wherein the inner coating layer and the outer coating layer do not contain any therapeutically active agent. This invention further relates to a method of maintaining the desired site of delivery of a therapeutic agent in the gastrointestinal tract by administering the above compositions to a human or lower animal | 04-03-2014 |
| 20140105993 | MODIFIED-RELEASE MICROPARTICLES BASED ON AMPHIPHILIC COPOLYMER AND ON ACTIVE PRINCIPLE(S) AND PHARMACEUTICAL FORMULATIONS COMPRISING THEM - The present invention relates to novel microparticles formed of amphiphilic polyamino acids which transport active principle(s), AP(s), in particular protein and peptide active principle(s), and to novel modified-release pharmaceutical formulations comprising said AP microparticles. Microparticles of amphiphilic polyamino acid (PO) may include at least one AP (associated noncovalently) which spontaneously form a colloidal suspension of nanoparticles in water, at pH 7.0, under isotonic conditions. The microparticles may be obtained by atomization of a solution or colloidal suspension of PO comprising at least one AP, may have a size of between 0.5 and 100 microns, and may be dispersible in colloidal suspension. | 04-17-2014 |
| 20140170224 | GELATIN-BASED MICROGELS - A gelatin-based microgel was prepared by a simple method starting from gelatin and alginate. The microgel was composed of a soft gelatin-based core coated by a permeable membrane. Gelatin-based core was moderately crosslinked by a novel crosslinker 4-arm PEG succinimidyl glutarate (pentaerytheritol core) (sPEG-4A-GS(10 k)). | 06-19-2014 |
| 20140255502 | NANOPARTICLE DRUG CARRIER, PHARMACEUTICAL COMPOSITION AND MANUFACTURING METHOD THEREOF - A pharmaceutical composition is provided. The pharmaceutical composition includes a nanoparticle, a shell and a drug, wherein the nanoparticle has an outer surface and the drug is mixed with the shell and is formed on the outer surface. | 09-11-2014 |
| 20140314860 | ENTERIC COATED MULTIPARTICULATE COMPOSITION WITH PROTEINACEOUS SUBCOAT - A multiparticulate composition includes a plurality of individual enteric coated cores containing one or more terpene-based active ingredients and having a continuous proteinaceous subcoating layer covering the individual cores and separating the individual cores from their respective enteric coatings. The continuous proteinaceous subcoating layer prevents volatile terpene-based active ingredients from leaving the core, even when the core is heated during processing or stored for long periods above room temperature. The multiparticulate composition may be used to treat gastrointestinal disorders. | 10-23-2014 |
| 20140348934 | ROTARY DIE SYSTEM - A rotary die system that includes first and second axially aligned, coacting rotary dies positioned adjacent one another. Each die includes a working surface having a plurality of recesses defined therein. The recesses in the first die are each configured to align with a recess in the second die to form a product cavity upon coaction of the first and second dies. The product cavity is configured to receive a product. Each recess in at least one of the first or second dies includes a pin therein that is configured to puncture a film that at least partially surrounds the product. | 11-27-2014 |
| 20140356440 | Enteric Coated Multiparticulate Controlled Release Peppermint Oil Composition and Related Methods - A multiparticulate composition is formed from a plurality of individual cores including a hydrophobic phase containing peppermint oil dispersed in a microcrystalline cellulose-based gel and a hydrophilic phase containing a hydrogel. An enteric coating is over the individual cores. The multiparticulate composition can be used to treat gastrointestinal disorders. | 12-04-2014 |
| 20150044294 | Enteric Coated Multiparticulate Composition With Proteinaceous Subcoat - A multiparticulate composition includes a plurality of individual enteric coated cores containing one or more terpene-based active ingredients and having a continuous proteinaceous subcoating layer covering the individual cores and separating the individual cores from their respective enteric coatings. The continuous proteinaceous subcoating layer prevents volatile terpene-based active ingredients from leaving the core, even when the core is heated during processing or stored for long periods above room temperature. The multiparticulate composition may be used to treat gastrointestinal disorders. | 02-12-2015 |
| 20150050352 | Enteric Coated Multiparticulate Composition With Proteinaceous Subcoat - A multiparticulate composition includes a plurality of individual enteric coated cores containing one or more terpene-based active ingredients and having a continuous proteinaceous subcoating layer covering the individual cores and separating the individual cores from their respective enteric coatings. The continuous proteinaceous subcoating layer prevents volatile terpene-based active ingredients from leaving the core, even when the core is heated during processing or stored for long periods above room temperature. The multiparticulate composition may be used to treat gastrointestinal disorders. | 02-19-2015 |
| 20150056291 | Adhesive Containing Microparticles - Methods for forming and incorporating microparticles containing one or more active agents into adhesives are described. The methods involve spray drying a liquid of the one or more active agents and obtaining the active agent in a particulate form. The dry powder is then blended or otherwise incorporated with the adhesive of interest. Also described are various medical products utilizing the adhesive and one or more active agents in microparticle form, and related methods of use. | 02-26-2015 |
| 20150064261 | Multiparticulate L-Menthol Formulations and Related Methods - A multiparticulate dosage form includes a plurality of individual spheroidal enteric coated particulates having (a) a diameter of 0.1 to 2.5 mm; (b) a solid core containing an effective amount of a combination of an L-menthol source and a terpene-based essential oil; (c) a continuous proteinaceous subcoating over the core; and (d) an enteric coating over the subcoating. The multiparticulate dosage form can be used to treat gastrointestinal disorders. | 03-05-2015 |
| 20160038429 | Enteric Coated Multiparticulate Composition With Proteinaceous Coating For Improved Storage Stability - A storage stable L-menthol composition includes a tablet, caplet, capsule, or sachet dosage form. The dosage form has (a) a plurality of individual cores containing an L-menthol source and at least one pharmaceutical excipient and (b) a proteinaceous coating of a continuous film of proteinaceous material over the individual cores forming a plurality of proteinaceous coated individual cores. The film is effective to substantially prevent L-menthol in the L-menthol source from leaving the individual cores when stored at a temperature of 40 degrees C. and 75% relative humidity for at least 1 day. The dosage form contains an effective amount of the L-menthol source for treating a gastrointestinal disorder. | 02-11-2016 |
| 20160095822 | Multiparticulate L-Menthol Formulations and Related Methods - A pharmaceutical dosage form includes an effective amount of L-menthol for treating a gastrointestinal disorder. The L-menthol is within a plurality of particulates having a core including crystalline L-menthol dissolved in a terpene-based essential oil. A proteinaceous coating of a continuous film of proteinaceous material is over the core. | 04-07-2016 |
| 20160200891 | POROUS GELS AND METHODS FOR THEIR PREPARATION | 07-14-2016 |
| 20160250380 | METHOD FOR MANUFACTURING SUPPORT FOR REGENERATING CORE-SHELL STRUCTURED HARD TISSUE AND SUPPORT FOR REGENERATING CORE-SHELL STRUCTURED HARD TISSUE MANUFACTURED THEREBY | 09-01-2016 |
